NEO-RIT - Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced KRAS Wildtype Rectal Cancer (Clinical Stages II and III).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jan 2016
At a glance
- Drugs Panitumumab (Primary)
- Indications Rectal cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms NEO-RIT
- 12 Jan 2016 Planned End Date changed from 1 Mar 2016 to 1 Jul 2016 as per ClinicalTrials.gov record.
- 12 Jan 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 08 Dec 2015 Planned End Date changed from 1 Jun 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.